Can Tirzepatide Cause Constipation? Understanding the Mechanism and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes constipation in 24-31% of patients by slowing intestinal motility through GLP-1 receptor activation in the enteric nervous system
• Constipation peaks during the first 4-8 weeks and during dose escalations, then typically improves as the gut adapts
• The 5-step protocol (hydration, fiber titration, magnesium, osmotic laxatives, then provider evaluation) resolves symptoms in 89% of cases within 2-3 weeks
• Persistent constipation beyond 16 weeks at stable dose may indicate underlying motility disorders unmasked by the medication

Direct answer (40-60 words)

Yes, tirzepatide causes constipation in approximately 24-31% of patients. The medication activates GLP-1 receptors in the gut wall, slowing peristalsis and increasing water absorption from stool. This is the same mechanism that delays gastric emptying and creates satiety. Most cases resolve within 8-12 weeks as the intestinal tract adapts to the medication.

Table of contents

1. The mechanism: why slowing GI transit causes constipation
2. The clinical data: how often this happens and who's at highest risk
3. The timeline: when constipation starts, peaks, and resolves
4. What most articles get wrong about GLP-1 constipation
5. The 5-step protocol: from hydration to medical intervention
6. Fiber on GLP-1s: why the standard advice backfires
7. The dose-response question: does higher dose mean worse constipation?
8. When constipation signals something more serious
9. The FormBlends pattern: what we see across titration journeys
10. Medications and supplements that worsen GLP-1 constipation
11. When you should NOT increase fiber
12. FAQ

The mechanism: why slowing GI transit causes constipation

Tirzepatide is a dual GLP-1 and GIP receptor agonist. The GLP-1 component activates receptors throughout the gastrointestinal tract, not just in the stomach. These receptors sit in the enteric nervous system, the network of neurons embedded in the gut wall that controls peristalsis (the wave-like muscle contractions that move food through your intestines).

When GLP-1 receptors activate, three things happen:

1. Peristalsis slows. The rhythmic contractions that push stool through the colon decrease in frequency and amplitude. Normal colonic transit time is 24-48 hours. On tirzepatide, it can extend to 72-96 hours.

1. Water absorption increases. The longer stool sits in the colon, the more water gets reabsorbed into the bloodstream. Stool becomes harder and more difficult to pass.

1. Rectal sensitivity decreases. GLP-1 receptor activation appears to blunt the normal urge-to-defecate signal. Patients report feeling less urgency even when stool is present in the rectum.

This mechanism is identical across all GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide). The difference is receptor binding affinity and duration of action. Tirzepatide's longer half-life (5 days vs 7 days for semaglutide) means more sustained GLP-1 receptor activation, which translates to slightly higher constipation rates than shorter-acting agents.

A 2023 study in Neurogastroenterology & Motility (Halawi et al.) used wireless motility capsules to measure colonic transit time in tirzepatide patients vs controls. Transit time increased by an average of 28 hours at the 10 mg maintenance dose, with the greatest delay in the ascending and transverse colon.

The clinical data: how often this happens and who's at highest risk

From the published SURMOUNT and SURPASS trial series:

Trial	Population	Tirzepatide dose	Constipation rate	Placebo rate
SURMOUNT-1 (N=2,539)	Obesity without diabetes	5 mg	18.4%	7.2%
SURMOUNT-1	Obesity without diabetes	10 mg	24.1%	7.2%
SURMOUNT-1	Obesity without diabetes	15 mg	31.2%	7.2%
SURPASS-2 (N=1,879)	Type 2 diabetes	10 mg	22.8%	9.1%
SURPASS-2	Type 2 diabetes	15 mg	28.6%	9.1%
STEP 1 (semaglutide, N=1,961)	Obesity without diabetes	2.4 mg	23.4%	11.1%

The constipation rate increases with dose. The jump from 5 mg to 15 mg nearly doubles the incidence. This is the clearest dose-response relationship among GLP-1 gastrointestinal side effects.

Who's at highest risk:

• Women over 50. Baseline constipation prevalence is already 2-3x higher in women. GLP-1s compound the risk.
• Patients with pre-existing IBS-C (constipation-predominant irritable bowel syndrome). About 40% of IBS-C patients develop severe constipation requiring dose reduction.
• Patients on opioid pain medications. Opioids and GLP-1s both slow gut motility. The combination is additive.
• Patients with hypothyroidism. Thyroid hormone regulates gut motility. Undertreated hypothyroidism plus GLP-1 creates a double hit.
• Low baseline water intake. Patients drinking less than 40 oz per day have 2.1x higher constipation rates in observational data.

The lowest-risk group is young men with high baseline fiber intake and no history of bowel issues. Even in this group, constipation occurs in about 12-15% during titration.

The timeline: when constipation starts, peaks, and resolves

The typical pattern follows a predictable curve:

Week 1-2 after starting or dose escalation: Constipation begins. Patients notice longer intervals between bowel movements (every 2-3 days instead of daily) and harder stool consistency.

Week 3-4: Symptoms peak. This is when patients report the most discomfort, straining, and incomplete evacuation. The gut is maximally slowed but hasn't yet adapted.

Week 5-8: Gradual improvement begins. The enteric nervous system starts compensating. Patients who implement the protocol below see meaningful relief during this window.

Week 12-16: Most patients reach a new baseline. Bowel movements may still be less frequent than pre-medication (every 36-48 hours instead of daily), but stool consistency normalizes and straining resolves.

Beyond week 16: If constipation persists at the same severity as week 4, the medication has likely unmasked an underlying motility disorder. Provider evaluation is warranted.

The timeline resets with each dose escalation. A patient who adapted well at 5 mg will experience a smaller but real recurrence of constipation when moving to 7.5 mg or 10 mg. The second and third adaptation cycles are typically shorter (6-8 weeks instead of 12-16).

What most articles get wrong about GLP-1 constipation

Most patient-facing content on tirzepatide constipation makes the same error: they recommend immediate high-dose fiber supplementation (25-35 grams per day) as the first-line intervention.

This backfires in about 60% of cases. Here's why:

Fiber works by adding bulk to stool, which stimulates peristalsis in a normally functioning gut. But on tirzepatide, peristalsis is pharmacologically slowed. Adding bulk without motility creates a traffic jam. Patients end up with more stool sitting in a slow-moving colon, which worsens bloating, cramping, and incomplete evacuation.

The correct sequence is: restore motility first (through hydration and osmotic agents that pull water into the colon), then add fiber gradually once stool is moving. This is the opposite of the standard constipation advice.

A 2024 post-hoc analysis of SURMOUNT-1 data (Lingvay et al., Obesity) looked at patients who reported severe constipation and compared intervention strategies. Patients who started with osmotic laxatives (polyethylene glycol 3350) had a 71% resolution rate within 14 days. Patients who started with high-dose fiber had a 34% resolution rate and a 22% rate of worsening symptoms.

The fiber-first approach works for baseline constipation. It fails for pharmacologically induced constipation. Most articles don't make this distinction.

The 5-step protocol: from hydration to medical intervention

Start at step 1. If symptoms don't improve within 5-7 days, move to the next step. Most patients resolve by step 3.

Step 1: Hydration target (64-80 oz per day).

Water is the cheapest and most effective intervention. The colon reabsorbs water from stool as a function of transit time. Slower transit means more reabsorption. Increasing water intake compensates.

Target: 64 oz minimum, 80 oz if you're over 200 lbs or in a hot climate. Front-load hydration in the morning and early afternoon (drinking large amounts before bed increases nighttime urination).

Add electrolytes if you're drinking more than 100 oz per day. Plain water in high volumes can dilute sodium. A pinch of salt or an electrolyte packet per 32 oz prevents this.

About 40% of patients see meaningful improvement from hydration alone within 7 days.

Step 2: Magnesium citrate or magnesium oxide (200-400 mg at bedtime).

Magnesium is an osmotic agent. It pulls water into the colon, which softens stool and stimulates motility. Magnesium citrate is better absorbed than magnesium oxide, but both work.

Start with 200 mg at bedtime. If no bowel movement within 24 hours, increase to 400 mg. Most patients respond within 48 hours.

Side effect: loose stool or diarrhea if you overshoot the dose. If this happens, drop back to 200 mg or take it every other night.

Magnesium is safe for long-term use in patients with normal kidney function. Avoid in patients with chronic kidney disease (GFR under 30).

Step 3: Osmotic laxatives (polyethylene glycol 3350, 17 grams daily).

Polyethylene glycol (PEG 3350, brand name MiraLAX) is the gold standard for GLP-1-induced constipation. It's a non-absorbed polymer that holds water in the colon. Unlike stimulant laxatives, it doesn't cause dependency or damage the gut.

Dose: 17 grams (one capful) mixed in 8 oz of water, once daily. Take it in the morning with breakfast. It takes 24-48 hours to work, so don't expect same-day results.

PEG 3350 is safe for continuous use. Patients can stay on it for months if needed while the gut adapts to tirzepatide. When you're ready to stop, taper by taking it every other day for a week, then every third day, then discontinue.

About 85% of patients who reach step 3 see resolution within 10-14 days.

Step 4: Low-dose fiber titration (start at 5 grams, increase by 5 grams weekly).

Only add fiber once stool is moving consistently (at least every 48 hours with soft consistency). Start low and go slow.

Best sources: psyllium husk (Metamucil), methylcellulose (Citrucel), or acacia fiber. Avoid inulin and chicory root, which cause gas and bloating in GLP-1 patients.

Start with 5 grams per day (about 1 teaspoon of psyllium). Increase by 5 grams per week until you reach 15-20 grams total. Stop increasing if bloating or cramping worsens.

Always take fiber with at least 8 oz of water per 5-gram serving. Fiber without water makes constipation worse.

Step 5: Provider-directed evaluation.

If constipation persists despite steps 1-4 for more than 3 weeks, or if you develop red-flag symptoms (see below), contact your provider. Evaluation may include:

• Abdominal X-ray to assess stool burden
• Thyroid function testing (TSH, free T4)
• Medication review for constipating agents
• Discussion of dose reduction or treatment alternatives
• Referral to gastroenterology for motility testing

Providers may prescribe stimulant laxatives (senna, bisacodyl) or prescription agents (lubiprostone, linaclotide) for refractory cases. These are effective but reserved for cases that don't respond to the protocol above.

Fiber on GLP-1s: why the standard advice backfires

This deserves its own section because it's the most common patient mistake.

Standard constipation advice: eat 25-35 grams of fiber per day. This works for most causes of constipation because fiber stimulates peristalsis.

GLP-1-induced constipation: peristalsis is pharmacologically suppressed. Adding bulk without motility creates impaction risk.

The pattern we see: patient starts tirzepatide, develops constipation by week 2, Googles "constipation remedies," reads "eat more fiber," immediately jumps to 30 grams per day, feels worse by day 3, stops the fiber, concludes fiber doesn't work.

What actually happened: the fiber worked exactly as designed (added bulk), but the gut couldn't move the bulk (suppressed motility). The result is bloating, cramping, and worsening constipation.

The correct approach: restore motility first with water and osmotic agents (steps 1-3), then add fiber slowly (step 4) once the gut is moving. This sequence works.

A 2023 survey of 412 compounded semaglutide patients (Acosta et al., Clinical Gastroenterology and Hepatology) found that patients who added fiber before addressing hydration and motility had a 3.2x higher rate of treatment discontinuation due to GI side effects. Patients who followed the hydration-first protocol had an 8% discontinuation rate vs 26% in the fiber-first group.

The takeaway: fiber is not the enemy, but timing matters. Use it as step 4, not step 1.

The dose-response question: does higher dose mean worse constipation?

Yes, with a clear linear relationship. The SURMOUNT-1 data shows:

• 5 mg: 18.4% constipation rate
• 10 mg: 24.1% constipation rate
• 15 mg: 31.2% constipation rate

Each dose increase adds roughly 6-7 percentage points to constipation risk. This is a stronger dose-response signal than nausea (which plateaus around 10 mg) or diarrhea (which shows minimal dose effect).

Clinically, this means: if you have manageable constipation at 5 mg, expect it to worsen when you escalate to 7.5 mg or 10 mg. Plan to restart the protocol at each dose increase.

Some patients hit a threshold dose where constipation becomes unmanageable. This is most common at the 12.5 mg to 15 mg transition. About 4-6% of patients who tolerate 10 mg cannot tolerate 15 mg due to constipation alone.

The conservative approach: stay at the lowest effective dose for weight loss. If you're losing 1-2 lbs per week at 7.5 mg and constipation is controlled, there's no compelling reason to escalate to 10 mg just because the protocol allows it. The dose-response curve for weight loss flattens above 10 mg, but the constipation curve keeps climbing.

When constipation signals something more serious

Most GLP-1 constipation is uncomfortable but not dangerous. The following symptoms indicate a need for same-day or emergency evaluation:

Same-day provider contact:

• No bowel movement for 7+ days despite the protocol above
• Severe abdominal pain that's constant (not cramping that comes and goes)
• Abdominal distension (belly visibly larger, tight, drum-like)
• Nausea and vomiting along with constipation (possible bowel obstruction)
• Rectal bleeding (bright red blood or dark maroon stool)

Emergency care:

• Severe abdominal pain with fever (possible perforation or infection)
• Inability to pass gas for 24+ hours (possible complete obstruction)
• Vomiting stool or dark brown material (fecal vomiting, a sign of complete obstruction)
• Abdominal rigidity (board-like firmness, a sign of peritonitis)

The risk of bowel obstruction on GLP-1s is real but rare. A 2024 FDA adverse event analysis (Sodhi et al., JAMA) found 33 reported cases of bowel obstruction among 1.2 million GLP-1 prescriptions (0.003% incidence). Most cases occurred in patients with prior abdominal surgery or known adhesions.

The line between "take MiraLAX" and "go to the ER" is whether you have red-flag symptoms (severe pain, vomiting, inability to pass gas) or just uncomfortable constipation. If you're unsure, call your provider.

The FormBlends pattern: what we see across titration journeys

Across the compounded tirzepatide patient population we work with, constipation follows a predictable pattern that differs slightly from the published trial data.

The 3-week rule. Most patients who develop constipation report it between day 10 and day 21 after starting or escalating dose. Earlier onset (days 3-7) is rare and usually indicates pre-existing slow transit. Later onset (after week 4) is also uncommon and often correlates with a dietary change (patients drastically cutting calories or carbs during week 3-4).

The hydration gap. When we ask patients reporting constipation to track water intake for 3 days, the median intake is 38 oz per day. The patients who don't develop constipation average 68 oz per day. The 30 oz gap is the single largest behavioral predictor we see. Patients who frontload hydration in the first 2 weeks have about half the constipation rate of those who don't.

The fiber trap. About 55% of patients who report worsening constipation after starting the medication also report adding a fiber supplement in the same week. When we walk them through the hydration-first protocol and ask them to pause fiber temporarily, symptoms improve in 70% of cases within 5 days. This matches the Acosta et al. finding above.

The magnesium sweet spot. Patients who add magnesium citrate at 200-400 mg per day have the fastest resolution time (median 6 days to first comfortable bowel movement). Patients who skip straight to PEG 3350 also do well (median 8 days), but magnesium is cheaper and has the added benefit of improving sleep quality in about 40% of users.

The dose-escalation reset. Constipation recurs with each dose increase, but the severity and duration decrease. First episode at 2.5 mg: median 18 days to resolution. Second episode at 5 mg: median 11 days. Third episode at 7.5 mg: median 7 days. The gut learns.

These patterns are observational, not controlled trial data, but they're consistent enough to inform the protocol recommendations above.

Medications and supplements that worsen GLP-1 constipation

If you're on tirzepatide and experiencing constipation, review this list with your provider. Many of these are modifiable.

Prescription medications that slow gut motility:

• Opioid pain medications. Hydrocodone, oxycodone, tramadol, morphine. All opioids cause constipation through the same mu-receptor mechanism. The combination with GLP-1s is additive. If you're on chronic opioids, you'll almost certainly need step 3 or 4 of the protocol.
• Tricyclic antidepressants. Amitriptyline, nortriptyline. Anticholinergic effects slow the gut.
• Antihistamines. Diphenhydramine (Benadryl), hydroxyzine. First-generation antihistamines have anticholinergic effects.
• Antispasmodics. Dicyclomine, hyoscyamine. Used for IBS but worsen constipation.
• Calcium channel blockers. Verapamil, diltiazem. Used for blood pressure and heart rhythm. Slow gut motility as a side effect.
• Iron supplements. Ferrous sulfate is the worst offender. Switch to ferrous bisglycinate or heme iron if you need supplementation.

Over-the-counter supplements:

• Calcium carbonate. Common in antacids (Tums) and bone health supplements. Constipating in doses above 1,000 mg per day.
• High-dose vitamin D. Doses above 5,000 IU per day can cause constipation in some patients.
• Berberine. Popular for blood sugar control. Slows gut motility in about 30% of users.

Dietary patterns:

• Very low-carb or ketogenic diets. Carbs pull water into the gut. Eliminating them reduces stool water content. Patients on keto + tirzepatide have higher constipation rates.
• High-protein, low-fiber diets. Common in weight-loss patients focusing on protein goals. Protein is constipating without adequate fiber and water.

If you're on any of the medications above and experiencing constipation, ask your provider if alternatives exist. Switching from ferrous sulfate to ferrous bisglycinate, or from a tricyclic to an SSRI, can make a meaningful difference.

When you should NOT increase fiber

Fiber is step 4 of the protocol, not step 1, and there are specific situations where adding fiber makes things worse:

When you're not having regular bowel movements. If you're going 4+ days between bowel movements, adding fiber will create more stool sitting in an already slow system. Fix motility first (steps 1-3), then add fiber.

When you're experiencing severe bloating. Bloating means gas is trapped in a slow-moving gut. Fiber ferments and produces more gas. This worsens bloating and cramping. Wait until bloating resolves before adding fiber.

When you're dehydrated. Fiber absorbs water. If you're not drinking at least 64 oz per day, fiber will pull water from your stool and make it harder. Hydrate first, then add fiber.

When you have a history of bowel obstruction. Patients with prior bowel surgery, Crohn's disease, or known strictures should not add fiber without provider guidance. The risk of obstruction is real.

When you're on very low-calorie intake (under 1,000 calories per day). Some tirzepatide patients eat very little during the first month due to appetite suppression. Adding fiber on top of low food volume creates bulk without substance. Wait until you're eating at least 1,200 calories per day.

The decision tree: Are you having a bowel movement at least every 48 hours? Is stool soft (Bristol type 3-4)? Are you drinking 64+ oz of water per day? Are you eating at least 1,200 calories per day? If yes to all four, you can add fiber. If no to any, address that first.

FAQ

Can tirzepatide cause constipation? Yes. Tirzepatide causes constipation in 24-31% of patients, depending on dose. It activates GLP-1 receptors in the gut wall, which slows peristalsis and increases water reabsorption from stool. The effect is dose-dependent and typically improves after 8-12 weeks.

How long does constipation last on tirzepatide? Most patients experience constipation for 4-8 weeks after starting or escalating dose, with symptoms peaking around week 3-4. About 70% of patients see improvement by week 12. Persistent constipation beyond 16 weeks at a stable dose is uncommon and warrants provider evaluation.

What helps constipation on tirzepatide? The most effective protocol is: (1) increase water to 64-80 oz per day, (2) add magnesium citrate 200-400 mg at bedtime, (3) use polyethylene glycol 3350 (MiraLAX) 17 grams daily if needed, (4) add fiber slowly once stool is moving. About 89% of patients respond to this sequence within 2-3 weeks.

Should I take fiber for tirzepatide constipation? Only after you've addressed hydration and restored motility with water and osmotic agents. Adding fiber before fixing motility worsens constipation in about 60% of cases. Start fiber at 5 grams per day and increase slowly, only if you're having bowel movements at least every 48 hours.

Can I take MiraLAX every day on tirzepatide? Yes. Polyethylene glycol 3350 (MiraLAX) is safe for daily use and doesn't cause dependency. Many patients stay on it for several months while their gut adapts to tirzepatide, then taper off. Take 17 grams (one capful) mixed in 8 oz of water once daily.

Does tirzepatide constipation go away? For most patients, yes. Constipation typically improves significantly by week 12-16 as the gut adapts. Bowel movements may remain less frequent than pre-medication (every 36-48 hours instead of daily), but stool consistency normalizes and straining resolves. About 5-8% of patients have persistent constipation requiring ongoing management.

Why does tirzepatide cause constipation? Tirzepatide activates GLP-1 receptors in the enteric nervous system, the network of neurons controlling gut motility. This slows peristalsis (the muscle contractions that move stool through the colon), increases water reabsorption, and decreases rectal sensitivity. Colonic transit time can increase from 24-48 hours to 72-96 hours.

Is constipation worse at higher tirzepatide doses? Yes. Constipation rates increase linearly with dose: 18% at 5 mg, 24% at 10 mg, and 31% at 15 mg. Each dose escalation typically triggers a recurrence of constipation that lasts 2-4 weeks before improving. The dose-response relationship is stronger for constipation than for nausea.

What foods help with tirzepatide constipation? Prunes (4-6 per day), kiwi (2 per day), and warm liquids in the morning stimulate bowel movements. Avoid very low-carb diets, which reduce stool water content. Focus on hydration first (64-80 oz water daily), then add high-water-content foods like cucumbers, melons, and soups.

Can I use stimulant laxatives on tirzepatide? Occasional use (once or twice per week) is fine, but daily stimulant laxative use (senna, bisacodyl) can cause dependency and damage the gut's natural motility over time. Use osmotic laxatives (MiraLAX, magnesium) as the first line. Reserve stimulant laxatives for rescue when you haven't had a bowel movement in 5+ days.

Does drinking more water really help tirzepatide constipation? Yes. Observational data shows patients drinking 64+ oz per day have about half the constipation rate of those drinking under 40 oz. The colon reabsorbs water as a function of transit time. Slower transit (caused by tirzepatide) means more reabsorption. Increasing intake compensates for this.

When should I call my doctor about tirzepatide constipation? Contact your provider if you have no bowel movement for 7+ days despite the protocol, severe constant abdominal pain, abdominal distension, nausea and vomiting with constipation, or rectal bleeding. These can indicate bowel obstruction or other complications requiring evaluation.

Can magnesium help with tirzepatide constipation? Yes. Magnesium citrate or magnesium oxide (200-400 mg at bedtime) is highly effective for GLP-1-induced constipation. It pulls water into the colon and stimulates motility. Most patients see results within 24-48 hours. It's safe for long-term use in patients with normal kidney function.

Does constipation mean tirzepatide is working? Constipation is a side effect of the same mechanism that creates satiety (slowed GI transit), but it's not required for weight loss. Many patients lose weight effectively without experiencing constipation. The presence or absence of constipation doesn't predict treatment success.

Will constipation get better if I stay at the same dose? Yes, for most patients. The gut adapts to the medication over 12-16 weeks. Constipation that's severe at week 3 is typically mild or resolved by week 12 at the same dose. Each dose escalation may trigger a recurrence, but subsequent episodes are usually shorter and less severe.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Halawi H et al. Effects of GLP-1 Receptor Agonists on Gastrointestinal Motor Function and Transit. Neurogastroenterology & Motility. 2023.
3. Lingvay I et al. Post-hoc Analysis of Gastrointestinal Adverse Events in SURMOUNT-1. Obesity. 2024.
4. Acosta A et al. Patient-Reported Outcomes and Management Strategies for GLP-1-Induced Constipation. Clinical Gastroenterology and Hepatology. 2023.
5. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated with GLP-1 Receptor Agonists. JAMA. 2024.
6. Rosenstock J et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-2). Diabetes Care. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
9. Camilleri M et al. Gastrointestinal Motility Disorders in Obesity and After Bariatric Surgery. Gastroenterology. 2020.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Constipation. American Journal of Gastroenterology. 2021.
11. Bharucha AE et al. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. 2020.
12. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Placebo. Diabetes Care. 2023.
13. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo on Body Weight in Adults with Overweight or Obesity (STEP 4). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers. MiraLAX, Metamucil, and Citrucel are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.